Primary Results From Impassion131, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of First-Line Paclitaxel +/- Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [21] Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial
    Bondarde, S.
    Kaklamani, V.
    Sahoo, T. Prasad
    Lokanatha, D.
    Raina, V.
    Jain, M.
    Schwartzberg, L.
    Gradishar, W. J.
    CANCER RESEARCH, 2010, 70
  • [22] A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)
    Dieras, V.
    Yardley, D.
    Romieu, G.
    Valero, V.
    Isakoff, S.
    Koeppen, H.
    Thurm, H.
    Teng, M.
    Campone, M.
    Mocci, S.
    CANCER RESEARCH, 2013, 73
  • [23] Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).
    Goel, Shom
    O'Shaughnessy, Joyce
    Tan, Antoinette R.
    Krastev, Boris Milev
    Rugo, Hope S.
    Aftimos, Philippe Georges
    Yardley, Denise A.
    Zoran, Andric
    Wolfgang, Curt Douglas
    Sorrentino, Jessica
    Tao, Wenli
    Beelen, Andrew Paul
    Malik, Rajesh K.
    Jain, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
    Brufsky, A.
    Kim, S. B.
    Zvirbule, Z.
    Eniu, A.
    Mebis, J.
    Sohn, J. H.
    Wongchenko, M.
    Chohan, S.
    Amin, R.
    Yan, Y.
    McNally, V
    Miles, D.
    Loi, S.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 652 - 660
  • [25] First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (vol 32, pg 983, 2021)
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V.
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V.
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (10) : 1308 - 1308
  • [26] LOTUS (NCT021 62719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) plus paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).
    Dent, Rebecca Alexandra
    Kim, Sung-Bae
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Isakoff, Steven
    Oliveira, Mafalda
    Saura, Cristina
    Wongchenko, Matthew
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (vol 32, pg 983, 2021)
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V.
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V.
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (12) : 1650 - 1650
  • [28] Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A
    Dent, Rebecca
    Kim, Sung-Bae
    Oliveira, Mafalda
    Barrios, Carlos
    O'Shaughnessy, Joyce
    Isakoff, Steven J.
    Saji, Shigehira
    Freitas-Junior, Ruffo
    Philco, Manuel
    Bondarenko, Igor
    Lian, Qinshu
    Bradley, Denise
    Hinton, Heather
    Wongchenko, Matthew J.
    Mani, Aruna
    Turner, Nicholas
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial
    Emens, Leisha
    Molinero, Luciana
    Adams, Sylvia
    Rugo, Hope S.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Barrios, Carlos
    Winer, Eric P.
    Chang, Ching-Wei
    Chui, Stephen Y.
    Schmid, Peter
    Loi, Sherene
    CANCER RESEARCH, 2021, 81 (04)
  • [30] A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
    Fuchs, C. S.
    Azevedo, S.
    Okusaka, T.
    Van Laethem, J. -L.
    Lipton, L. R.
    Riess, H.
    Szczylik, C.
    Moore, M. J.
    Peeters, M.
    Bodoky, G.
    Ikeda, M.
    Melichar, B.
    Nemecek, R.
    Ohkawa, S.
    Swieboda-Sadlej, A.
    Tjulandin, S. A.
    Van Cutsem, E.
    Loberg, R.
    Haddad, V.
    Gansert, J. L.
    Bach, B. A.
    Carrato, A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 921 - 927
12345